摘要
胎儿来源的ＬＡＫ细胞／ｒＩＬ－２对５例失去手术、化疗、放疗机会的晚期恶性肿瘤病人进行了过继免疫治疗。结果都取得了一定的疗效，黑色素瘤病人肺转移结节基本消失，局部瘤细胞全部坏死，组织细胞正常；淋巴瘤病人转移灶消退５９％；小肠平滑肌肉瘤病人在没进行此疗法之前２年半复发、手术三次。第三次手术后用此疗法治疗一个疗程，三年后第一次复发。为晚期恶性肿瘤病人延长了生命，提高了生存质量争得了再次治疗的机会。
Five advanced malignant tumor were treated with LAK cells isolated from human fetal spleen combined with rIL-2. One patient with malignant melanoma had metastasis tumor dispeared in one lung and significantly reduced in the other. The matastasis lesion of one patient with lymphoma decreased 59% after treatment, a patient with intestinal smooth muscle sarcoma had prolonged relapse by administrated LAK/rIL-2. NO serious effects were observed.The results indicated that LAK/ rIL-2 in the treatment of patient with advanced malignant tumor is effect and safe.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
1995年第1期12-13,共2页
Cancer Research on Prevention and Treatment
关键词
基因重组
白细胞介素2
癌
免疫疗法
LAK细胞
Lympboma-activated kill cell (LAK cell)
Recombined interleukin-2 (rIL-2)
Fatal
Immunotherapy
